Tabula Rasa HealthCare Inc (NASDAQ: TRHC) expects Q2 sales of $72 – $73 million, exceeding the prior guidance range of $66 – $69 million and the consensus of $67.61 million.
Gordon Tunstall, TRHC's Lead Independent Director, said that the Board and management team have spoken with Indaba Capital Management on multiple occasions since their initial investment in April to understand their point of view."
Yesterday, Indaba issued a letter calling for the removal of Tabula Rasa's top executives.
According to Indaba, the TRHC board should dismantle the husband-and-wife management team over conflicts of interest and sustained value destruction since the IPO in 2016.
The largest investor calls for the resignations of CEO and Chairman Calvin Knowlton, Executive Director Orsula Knowlton, and lead independent director Gordon Tunstall after receiving sizable "withhold" votes at the 2022 annual meeting.
Indaba says Tunstall cannot be deemed truly "independent" given his long-standing ties to the Knowltons.
Price Action: TRHC shares are up 10.7% at $2.88 during the premarket session on the last check Thursday.
See more from Benzinga
Quest Diagnostics Lifts Annual Guidance On Higher COVID-19 Test Revenue Anticipation
HilleVax's Norovirus Vaccine Shows Long-Term Immunogenicity
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
